Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Firas Kara

Internal Medicine Fort Wayne, IN Medical Doctor

NPI 1700110822 CMS profile 924180

7615 W Jefferson Blvd, Fort Wayne, IN 46804

Open in the dashboard

General payments

$9,711

517 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Firas Kara of Fort Wayne, IN is reported in the CMS Open Payments database as having received $9,711 across 517 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $348 14
2024 General $631 20
2023 General $584 28
2022 General $1,424 88
2021 General $2,541 154
2020 General $1,685 98
2019 General $2,498 115

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Firas Kara
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Firas Kara were reported at $348. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Firas Kara Internal Medicine median Middle half National median
2019 $2,498 $159 $48–$570 $163
2020 $1,685 $119 $33–$402 $114
2021 $2,541 $135 $37–$521 $132
2022 $1,424 $141 $42–$496 $149
2023 $584 $149 $45–$519 $160
2024 $631 $154 $47–$537 $164
2025 $348 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $814 10 payments
  2. Lilly USA, LLC $622 22 payments
  3. Flexion Therapeutics, Inc. $620 27 payments
  4. Medtronic, Inc. $604 21 payments
  5. Collegium Pharmaceutical, Inc. $561 46 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $538 70 payments
  7. Biohaven Pharmaceutical Holding Company Ltd. $485 23 payments
  8. Supernus Pharmaceuticals, Inc. $468 33 payments
  9. Teva Pharmaceuticals USA, Inc. $440 9 payments
  10. US WorldMeds, LLC $350 23 payments
  11. Other $4,212 233 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,711 517 payments
Products named General payments · program years 2019–2025
  1. NURTEC ODT $756 46 payments
  2. Zilretta $620 27 payments
  3. Proclaim Family of SCS IPGs $518 5 payments
  4. XTAMPZA $503 45 payments
  5. RELISTOR $471 67 payments
  6. TROKENDI XR $468 33 payments
  7. Qutenza $305 15 payments
  8. MYOBLOC $303 20 payments
  9. RESTORE Spinal Cord Neurostimulation $296 5 payments
  10. RESTORE Spinal Cord Neurostimulation $242 14 payments
  11. Other $5,332 259 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 57 drugs

Part D claims

5,658

Median for Internal Medicine: 777

Drug cost

$721,541

Median for Internal Medicine: $73,373

Branded share of claims

45.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Qutenza Capsaicin/Skin Cleanser Brand 52 $130,133
Meloxicam Meloxicam, Submicronized Brand 156 $100,565
Percocet Oxycodone Hcl/Acetaminophen Brand 13 $56,971
Mounjaro Tirzepatide Brand 47 $49,861
Nurtec Odt Rimegepant Sulfate Brand 40 $47,284
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 1,127 $40,146
Ozempic Semaglutide Brand 37 $38,665
Cyclobenzaprine Hcl Generic 445 $37,678
Emgality Pen Galcanezumab-Gnlm Brand 25 $24,086
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 729 $22,950

The 10 drugs with the highest cost, of 57 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$94,752

Of which drugs: $22,125

Medicare patients

72

Average age 62

Services billed

10,041

47 women, 25 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Diabetes 44%
COPD 38%
Depression 38%
Ischemic heart disease 28%
Chronic kidney disease 24%
Heart failure 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 28 2,642 $271
Injection, methylprednisolone acetate, 40 mg J1030 Office 13 19 $77
5% dextrose/normal saline (500 ml = 1 unit) J7042 Office 11 13 $12

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QUVIVIQ
  • IDORSIA PHARMACEUTICALS US INC $181
$181 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $134
$134 — —
ZEPBOUND
  • Lilly USA, LLC $128
$128 — —
BOTOX
  • AbbVie, Inc. $18
$18 — —
JARDIANCE
  • Lilly USA, LLC $7
$7 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

517 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record